San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

Findings of a quality improvement initiative identified several gaps in guideline-aligned patient-centered care in HER2+ metastatic breast cancer (MBC), providing opportunities to implement action plans that improve patient outcomes in the community setting. Read More ›

Hypothesis-generating findings of a retrospective study in a small cohort of tucatinib-treated patients indicates a potential correlation between KMT2C mutations and unfavorable clinical outcomes. Read More ›

Real-world data from a large, prospective, single-institution cohort of older patients with metastatic breast cancer (MBC) indicated poor survival outcomes with increasing age, particularly for those aged >80 years. Read More ›

Exploratory data indicate that an immunohistochemistry (IHC) score of 3+ is less likely to be associated with lymph node and visceral metastases in patients with HER2+ metastatic breast cancer (MBC), and that site of metastasis has prognostic value in both the IHC 3+ and IHC 2+ subgroups. Read More ›

Results of a single-institution chart review indicated that central nervous system (CNS) involvement directly correlated with CNS-related death in patients with metastatic breast cancer (MBC), with greatest risk in those with leptomeningeal disease. Read More ›

An algorithm of composite biomarkers and pathological variables is associated with predicting progression-free survival and overall survival in patients with HR+/HER2-metastatic breast cancer. Read More ›

Study finds older women with metastatic breast cancer in Nigeria benefit from belonging to a peer support group. Read More ›

Recent study results find mutations in the ESR1 gene directly promote resistance to CDK4/6 inhibitors used alone or in combination with antiestrogens. Read More ›

Recent analysis finds that Black and younger patients with metastatic breast cancer are more likely to receive chemotherapy first-line and less likely to receive CDK4/6 inhibitors when receiving endocrine therapy. Read More ›

Qualitative study finds the presence of children or grandchildren is a primary treatment decision factor for women with metastatic breast cancer. Read More ›

Page 2 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications